Loading
Life sciences · Journal article
Advances in Clinical Medical Research · September 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: This study evaluated the prognostic significance of Tumor markers and Acute Phase Reactant Proteins(APRP) in colon cancer patients before and after therapy with different clinical status i.e. stable, progressive disease andimproved disease conditions. Materials and Methods: Fifty clinically diagnosed patients with colon cancers participated inthe study. Prognostic significance of tumor markers i.e. Carcinoembryonic antigen (CEA), Carbohydrate antigen (CA19-9)beta Human Chorionic Gonadotropin (β-HCG) and Acute phase reactant proteins including C-Reactive Protein (CRP) andAlpha-1-Antitrypsin (A1AT) were analyzed by comparing pretreatment levels with post treatment levels according toclinically evaluated disease status. Results: Mean serum level of tumor markers and acute phase reactant proteins weresignificantly higher in progressive disease when compared with levels before therapy CEA (t=2.108, p<0.05) CA19-9(t=1.995, p<0.05) β-HCG (t=0.961, p<0.05) CRP (t=2.010, p<0.05) A1AT (t=2.132, p<0.05). A nonsignificant change inmean serum level of tumor markers and acute phase reactant proteins were seen in stable condition when compared withlevels before therapy CEA (t=1.967, p>0.05) CA19-9 (t=1.490, p>0.05) β-HCG (t=0.945, p>0.05) CRP (t=1.942, p>0.05)A1AT (t=1.831, p>0.05). Mean serum level of tumor markers and acute phase reactant proteins were significantly lower inimproved condition when compared with levels before therapy CEA (t=4.856, p<0.001) CA19-9 (t=0.982, p<0.05) β-HCG(t=0.973, p<0.05) CRP (t=4.856, p<0.001) A1AT (t=2.515, p<0.05). Conclusion: Tumor markers CEA, CA19-9, Beta-HCGand Acute phase reactant proteins CRP, A1AT can be used as prognostic markers in the management of colon cancerpatients following therapy.